Lyso-Gb1 is one of the best predictors of clinical response in Gaucher disease, and FLT201 showed rapid and sustained reductions in lyso-Gb1 in its Phase 1/2 GALILEO-1 trial. Full approval would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback